Papaverine Targets STAT Signaling: A Dual‐Action Therapy Option Against SARS‐CoV‐2
Journal of Medical Virology · 2025
DOI: 10.1002/jmv.70319 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Philipp Reus und 9 weiteren Autor:innen. Beteiligte Einrichtung: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, ScreeningPort, Hamburg, Germany. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, COVID-19 Drug Treatment, Papaverine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported by the Frankfurter Stiftung für krebskranke Kinder, the Goethe-Corona-Fonds, Heinrich und Fritz Riese-Stiftung, CoroPan consortium fun….
Abstract (Originalsprache)
Papaverine (PV) has been previously identified as a promising candidate in SARS‐CoV‐2 repurposing screens. In this study, we further investigated both its antiviral and immunomodulatory properties. PV displayed antiviral efficacy against SARS‐CoV‐2 and influenza A viruses H1N1 and H5N1 in single infection as well as in co‐infection. We demonstrated PV's activity against various SARS‐CoV‐2 variants and identified its action at the post‐entry stage of the viral life cycle. Notably, treatment of air‐liquid interface (ALI) cultures of primary bronchial epithelial cells with PV significantly inhibited SARS‐CoV‐2 levels. Additionally, PV was found to attenuate interferon (IFN) signaling independently of viral infection. Mechanistically, PV decreased the activation of the IFN‐stimulated response element following stimulation with all three IFN types by suppressing STAT1 and STAT2 phosphorylation and nuclear translocation. Furthermore, the combination of PV with approved COVID‐19 therapeutics molnupiravir and remdesivir demonstrated synergistic effects. Given its immunomodulatory effects and clinical availability, PV shows promising potential as a component for combination therapy against COVID‐19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, ScreeningPort, Hamburg, Germany.
- Institute for Medical Virology, University Hospital, Goethe University Frankfurt, Frankfurt, Germany.
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany.
- Dr. Petra Joh Research Institute, Frankfurt, Germany.
ORCID-Profile: Philipp Reus
Förderung
- This study was supported by the Frankfurter Stiftung für krebskranke Kinder, the Goethe-Corona-Fonds, Heinrich und Fritz Riese-Stiftung, CoroPan consortium fun…
Zitieren
APA
Reus, P., Torbica, E., Rothenburger, T., Bechtel, M., Kandler, J., Ciesek, S., Gribbon, P., Kannt, A., Cinatl, J., & Bojkova, D. (2025). Papaverine Targets STAT Signaling: A Dual‐Action Therapy Option Against SARS‐CoV‐2. Journal of Medical Virology. https://doi.org/10.1002/jmv.70319
Vancouver
Reus P, Torbica E, Rothenburger T, Bechtel M, Kandler J, Ciesek S, et al. Papaverine Targets STAT Signaling: A Dual‐Action Therapy Option Against SARS‐CoV‐2. Journal of Medical Virology. 2025. doi:10.1002/jmv.70319
BibTeX
@article{Reus2025,
author = {Reus, Philipp and Torbica, Emma and Rothenburger, Tamara and Bechtel, Marco and Kandler, Joshua and Ciesek, Sandra and Gribbon, Philip and Kannt, Aimo and Cinatl, Jindrich and Bojkova, Denisa},
title = {Papaverine Targets STAT Signaling: A Dual‐Action Therapy Option Against SARS‐CoV‐2},
journal = {Journal of Medical Virology},
year = {2025},
doi = {10.1002/jmv.70319}
}
EUVIMED